Serum levels of iCAF-derived osteoglycin predict favorable outcome in pancreatic cancer.

"for the meta-analysis data from publicly available transcriptomic (microarray or rna-seq) data sets (e-mtab-6830 gse36924 gse15471 gse71729 gse21501 and tcga-paad ) with survival data were downloaded from the data repository gene expression omnibus (geo).; the novel postpancreatitis single-cell rna-sequencing data generated in our study is available in geo under accession number gse197908. data availability statement the gene expression data set from pdac pdx are available at e-mtab-6830"

"CONFLICT OF INTEREST Maarten F. Bijlsma has received research funding from Celgene, Frame Therapeutics and LeadPharma, and has acted as a consultant to Servier. Hanneke W. M. van Laarhoven has served as a consultant for BMS, Dragonfly, Lilly, Merck, Nordic Pharma and Servier, and has received unrestricted research funding and/or study medication from Bayer, BMS, Celgene, Janssen, Incyte, Lilly, Merck, Nordic Pharma, Philips, Roche and Servier, and has been a speaker for Astellas and Novartis. Jan Paul Medema has acted as a consultant to AbbVie. Louis Vermeulen received consultancy fees from Bayer, MSD, Genentech, Servier and Pierre Fabre. None of these parties were involved in the design of our study or drafting of the study. The other authors have no conflict of interest to declare."

"Funding information KWF Kankerbestrijding; Oncode Institute; PRECODE, Grant/Award Number: H2020‐MSCA‐ITN 861196; The AMC Foundation; The CCA Foundation"